Refile: AbbVie's migraine treatment meets late-stage study goal
10/09/2026 14:01
REFILE-AbbVie's migraine treatment meets late-stage study goal Corrects keyword used by media clients to "ABBVIE-MIGRAINE/STUDY" from "ABBVIE-MIGRANE STUDY/"
Sept 10 (Reuters) - AbbVie ABBV.N said on Thursday its migraine treatment had met the main goal of a late-stage study testing it as a preventive treatment of menstrual migraine in adults.
(Reporting by Sneha S K in Bengaluru; Editing by Shreya Biswas)
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96